(Total Views: 518)
Posted On: 10/05/2024 9:31:42 PM
Post# of 154138
* This study was funded by the United States Department of Defense (DOD) under award number W81XWH-18-1-0094
That's from our LL-FcRn paper.
DOD history of W81XWH-18-1-0094
TITLE:
A Fetus-Targeted Antibody Therapy to Prevent. Zika Virus Infection During Pregnancy
https://discover.dtic.mil/results/?q=W81XWH-1...gsc.page=1
Notice the Pi on Zika trial, is Diogo Magnani.
His LinkedIn:
https://www.linkedin.com/posts/diogomagnani_i...89312-i1mc
Success against HIV & very certain Zika becomes next targeted disease.
The 2nd phase of LL-PLS could very well already be 8-9 months under development.
All @ no cost to Cytodyn shareholders.
That's from our LL-FcRn paper.
DOD history of W81XWH-18-1-0094
TITLE:
A Fetus-Targeted Antibody Therapy to Prevent. Zika Virus Infection During Pregnancy
https://discover.dtic.mil/results/?q=W81XWH-1...gsc.page=1
Notice the Pi on Zika trial, is Diogo Magnani.
His LinkedIn:
https://www.linkedin.com/posts/diogomagnani_i...89312-i1mc
Success against HIV & very certain Zika becomes next targeted disease.
The 2nd phase of LL-PLS could very well already be 8-9 months under development.
All @ no cost to Cytodyn shareholders.
(10)
(0)
